CHAIN of INFECTION Disease

Total Page:16

File Type:pdf, Size:1020Kb

CHAIN of INFECTION Disease Infectious CHAIN OF INFECTION Disease For an infection to develop, Susceptible Reservoir Host each link of the chain must be connected. Breaking any link of the chain Portal of Portal of Entry Exit can stop the transmission of infection! Mode of Transmission INFECTIOUS DISEASE Any microorganism that can cause a disease such as a bacterium, virus, parasite, or fungus. Reasons that the organism will cause an infection are virulence (ability to multiply and grow), invasiveness (ability to enter tissue), and pathogenicity (ability to cause disease). RESERVOIR The place where the microorganism resides, thrives, and reproduces, i.e., food, water, toilet seat, elevator buttons, human feces, respiratory secretions. PORTAL OF EXIT The place where the organism leaves the reservoir, such as the respiratory tract (nose, mouth), intestinal tract (rectum), urinary tract, or blood and other body fluids. MODE OF TRANSMISSION The means by which an organism transfers from one carrier to another by either direct transmission (direct contact between infectious host and susceptible host) or indirect transmission (which involves an intermediate carrier like an environmental surface or piece of medical equipment). PORTAL OF ENTRY The opening where an infectious disease enters the host’s body such as mucus membranes, open wounds, or tubes inserted in body cavities like urinary catheters or feeding tubes. SUSCEPTIBLE HOST The person who is at risk for developing an infection from the disease. Several factors make a person more susceptible to disease including age (young people and elderly people generally are more at risk), underlying chronic diseases such as diabetes or asthma, conditions that weaken the immune system like HIV, certain types of medications, invasive devices like feeding tubes, and malnutrition. Summer 2011 .
Recommended publications
  • Commentary Disease Transmission Dynamics and the Evolution
    Proc. Natl. Acad. Sci. USA Vol. 96, pp. 800–801, February 1999 Commentary Disease transmission dynamics and the evolution of antibiotic resistance in hospitals and communal settings Simon A. Levin*† and Viggo Andreasen‡ *Department of Ecology and Evolutionary Biology, Eno Hall, Princeton University, Princeton NJ 08544; and ‡Department of Mathematics, Roskilde University, DK-4000 Roskilde, Denmark Despite the tremendous benefits of antibiotics for dealing with sally, exercising little influence on their host under normal a wide range of pathogens, there is by now little doubt that conditions. Antibiotics are typically introduced to treat the their indiscriminate use has led to the emergence of novel true pathogens, and for them the problem of resistance resistant strains and a frightening new set of threats to public introduces questions concerning the length and intensity of health. Hospitals and other community settings provide an treatment, multidrug strategies, and patient compliance. (See, especially fertile ground for the spread of those types; in for example, refs. 2–4). Commensals provide a different sort particular, the recent emergence and proliferation of bacteria of problem, however. Under normal conditions, they live in resistant to both methicillin and vancomycin has engendered such places as the skin or upper respiratory tract, causing little serious concern, threatening the effectiveness of the last or no harm. On occasion, however, they become translocated available options for treatment of potentially fatal Staphylo- to sites that are normally sterile, such as the blood or lungs, coccus strains. where they may have serious harmful effects (6). Many viru- It seems clear that a considered and comprehensive strategy lence factors, for example in Staphylococcus aureus, are carried for antibiotic use is essential, permitting the intelligent de- on plasmids, and can be exchanged among different strains.
    [Show full text]
  • Valacyclovir Reduced Genital Herpes Transmission in Couples Discordant for Herpes Simplex Virus Type 2 Infection Corey L, Wald A, Patel R, Et Al
    146 THERAPEUTICS Evid Based Med: first published as 10.1136/ebm.9.5.146 on 30 September 2004. Downloaded from Valacyclovir reduced genital herpes transmission in couples discordant for herpes simplex virus type 2 infection Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350:11–20. Clinical impact ratings GP/FP/Primary care wwwwwwq Infectious diseases wwwwwqq ............................................................................................................................... In heterosexual couples who are serologically discordant for herpes simplex virus type 2 (HSV-2) infection, does once Q daily valacyclovir reduce the sexual transmission of genital herpes? METHODS MAIN RESULTS The table shows the results. Design: randomised placebo controlled trial. CONCLUSION In heterosexual couples discordant for herpes simplex virus type 2 infection, valacyclovir reduced transmission of infection. Allocation: concealed.* Commentary Blinding: blinded {participants, healthcare providers, data revious studies have shown that antiviral drugs can reduce the collectors, data analysts, and outcome assessors}À.* frequency of recurrence and subclinical shedding of viral particles.1 Follow up period: 8 months. P This important, large, well designed trial by Corey et al is the first to show an effect on the transmission of HSV-2 infection to an uninfected partner. In this study, the reduction in transmission was limited; 62 partners had Setting: 96 sites in the US, Canada, Europe, Latin America, and to take the drug daily for 8 months to prevent 1 infection, and 57 partners Australia. had to take the drug daily to prevent overall acquisition of HSV-2 infection. 2 independent predictors were found in addition to the drugs: Participants: 1498 couples >18 years who were women as the susceptible partners (hazard ratio [HR] 3.3) and duration immunocompetent, heterosexual, monogamous, in good health, of HSV-2 infection ,2 years (HR 2.9).
    [Show full text]
  • Potential for Transmission of Antimicrobial Resistance In
    Report of the Scientific Committee of the Food Safety Authority of Ireland 2015 Potential for Transmission of Antimicrobial Resistance in the Food Chain Report of the Scientific Committee of the Food Safety Authority of Ireland Potential for Transmission of Antimicrobial Resistance in the Food Chain Published by: Food Safety Authority of Ireland Abbey Court, Lower Abbey St Dublin 1 DO1 W2H4 Tel: +353 1 8171300 Fax: +353 1 8171301 [email protected] www.fsai.ie © FSAI 2015 Applications for reproduction should be made to the FSAI Information Unit ISBN 978-1-910348-01-7 Report of the Scientific Committee of the Food Safety Authority of Ireland Potential for Transmission of Antimicrobial Resistance in the Food Chain CONTENTS FOREWORD 4 ACKNOWLEDGEMENTS 5 ABBREVIATIONS 6 EXECUTIVE SUMMARY 7 CHAPTER 1. INTRODUCTION 10 1.1 The Scale of the Antimicrobial Resistance Problem ...................10 1.2 Human and Animals – The ‘One Health’ Concept.....................11 1.3 The Background to the Antimicrobial Resistance Problem . .11 1.4 Genetic Diversity, Genetic Determinants and Change in Bacteria . 14 1.5 Selection for Antimicrobial Resistance...............................15 1.6 Surveillance of Antimicrobial Resistance in Ireland and Europe . .15 1.7 Prudent Use of Antimicrobials – Definition . 15 1.8 Surveillance of Antimicrobial Use in Ireland and Europe ...............16 1.9 Antimicrobials and the Food Chain . .16 1.10 Antimicrobial-resistant Bacteria and the Food Chain ..................16 1.11 Summary . .17 1.12 Chapter Bibliography..............................................17 CHAPTER 2. TERMS OF REFERENCE 20 2.1 Chapter Bibliography..............................................20 1 of 58 Report of the Scientific Potential for Transmission of Committee of the Food Safety Authority of Ireland Antimicrobial Resistance in the Food Chain CHAPTER 3.
    [Show full text]
  • Zoonotic Diseases Fact Sheet
    ZOONOTIC DISEASES FACT SHEET s e ion ecie s n t n p is ms n e e s tio s g s m to a a o u t Rang s p t tme to e th n s n m c a s a ra y a re ho Di P Ge Ho T S Incub F T P Brucella (B. Infected animals Skin or mucous membrane High and protracted (extended) fever. 1-15 weeks Most commonly Antibiotic melitensis, B. (swine, cattle, goats, contact with infected Infection affects bone, heart, reported U.S. combination: abortus, B. suis, B. sheep, dogs) animals, their blood, tissue, gallbladder, kidney, spleen, and laboratory-associated streptomycina, Brucellosis* Bacteria canis ) and other body fluids causes highly disseminated lesions bacterial infection in tetracycline, and and abscess man sulfonamides Salmonella (S. Domestic (dogs, cats, Direct contact as well as Mild gastroenteritiis (diarrhea) to high 6 hours to 3 Fatality rate of 5-10% Antibiotic cholera-suis, S. monkeys, rodents, indirect consumption fever, severe headache, and spleen days combination: enteriditis, S. labor-atory rodents, (eggs, food vehicles using enlargement. May lead to focal chloramphenicol, typhymurium, S. rep-tiles [especially eggs, etc.). Human to infection in any organ or tissue of the neomycin, ampicillin Salmonellosis Bacteria typhi) turtles], chickens and human transmission also body) fish) and herd animals possible (cattle, chickens, pigs) All Shigella species Captive non-human Oral-fecal route Ranges from asymptomatic carrier to Varies by Highly infective. Low Intravenous fluids primates severe bacillary dysentery with high species. 16 number of organisms and electrolytes, fevers, weakness, severe abdominal hours to 7 capable of causing Antibiotics: ampicillin, cramps, prostration, edema of the days.
    [Show full text]
  • The Resistance to Host Antimicrobial Peptides in Infections Caused by Daptomycin-Resistant Staphylococcus Aureus
    antibiotics Communication The Resistance to Host Antimicrobial Peptides in Infections Caused by Daptomycin-Resistant Staphylococcus aureus Md Saruar Bhuiyan 1,† , Jhih-Hang Jiang 1,† , Xenia Kostoulias 1, Ravali Theegala 1, Graham J. Lieschke 2 and Anton Y. Peleg 1,3,* 1 Infection and Immunity Program, Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, VIC 3800, Australia; [email protected] (M.S.B.); [email protected] (J.-H.J.); [email protected] (X.K.); [email protected] (R.T.) 2 Australian Regenerative Medicine Institute, Monash University, Clayton, VIC 3800, Australia; [email protected] 3 Department of Infectious Diseases, The Alfred Hospital and Central Clinical School, Monash University, Melbourne, VIC 3004, Australia * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: Daptomycin is an important antibiotic for the treatment of infections caused by Staphylococcus aureus. The emergence of daptomycin resistance in S. aureus is associated with treatment failure and persistent infections with poor clinical outcomes. Here, we investigated host innate immune responses against clinically derived, daptomycin-resistant (DAP-R) and -susceptible S. aureus paired isolates using a zebrafish infection model. We showed that the control of DAP-R S. aureus infections was attenuated in vivo due to cross-resistance to host cationic antimicrobial Citation: Bhuiyan, M.S.; Jiang, J.-H.; peptides. These data provide mechanistic understanding into persistent infections caused by DAP-R Kostoulias, X.; Theegala, R.; Lieschke, S. aureus and provide crucial insights into the adaptive evolution of this troublesome pathogen. G.J.; Peleg, A.Y. The Resistance to Host Antimicrobial Peptides in Keywords: S.
    [Show full text]
  • Evolution of Disease Transmission During the COVID-19
    www.nature.com/scientificreports OPEN Evolution of disease transmission during the COVID‑19 pandemic: patterns and determinants Jie Zhu & Blanca Gallego* Epidemic models are being used by governments to inform public health strategies to reduce the spread of SARS‑CoV‑2. They simulate potential scenarios by manipulating model parameters that control processes of disease transmission and recovery. However, the validity of these parameters is challenged by the uncertainty of the impact of public health interventions on disease transmission, and the forecasting accuracy of these models is rarely investigated during an outbreak. We ftted a stochastic transmission model on reported cases, recoveries and deaths associated with SARS‑CoV‑2 infection across 101 countries. The dynamics of disease transmission was represented in terms of the daily efective reproduction number ( Rt ). The relationship between public health interventions and Rt was explored, frstly using a hierarchical clustering algorithm on initial Rt patterns, and secondly computing the time‑lagged cross correlation among the daily number of policies implemented, Rt , and daily incidence counts in subsequent months. The impact of updating Rt every time a prediction is made on the forecasting accuracy of the model was investigated. We identifed 5 groups of countries with distinct transmission patterns during the frst 6 months of the pandemic. Early adoption of social distancing measures and a shorter gap between interventions were associated with a reduction on the duration of outbreaks. The lagged correlation analysis revealed that increased policy volume was associated with lower future Rt (75 days lag), while a lower Rt was associated with lower future policy volume (102 days lag).
    [Show full text]
  • Chapter 2 Disease and Disease Transmission
    DISEASE AND DISEASE TRANSMISSION Chapter 2 Disease and disease transmission An enormous variety of organisms exist, including some which can survive and even develop in the body of people or animals. If the organism can cause infection, it is an infectious agent. In this manual infectious agents which cause infection and illness are called pathogens. Diseases caused by pathogens, or the toxins they produce, are communicable or infectious diseases (45). In this manual these will be called disease and infection. This chapter presents the transmission cycle of disease with its different elements, and categorises the different infections related to WES. 2.1 Introduction to the transmission cycle of disease To be able to persist or live on, pathogens must be able to leave an infected host, survive transmission in the environment, enter a susceptible person or animal, and develop and/or multiply in the newly infected host. The transmission of pathogens from current to future host follows a repeating cycle. This cycle can be simple, with a direct transmission from current to future host, or complex, where transmission occurs through (multiple) intermediate hosts or vectors. This cycle is called the transmission cycle of disease, or transmission cycle. The transmission cycle has different elements: The pathogen: the organism causing the infection The host: the infected person or animal ‘carrying’ the pathogen The exit: the method the pathogen uses to leave the body of the host Transmission: how the pathogen is transferred from host to susceptible person or animal, which can include developmental stages in the environment, in intermediate hosts, or in vectors 7 CONTROLLING AND PREVENTING DISEASE The environment: the environment in which transmission of the pathogen takes place.
    [Show full text]
  • STD (Sexually Transmitted Disease) Or STI (Sexually Transmitted Infection): Should We Choose? Janet Byron Anderson, Phd
    STD (sexually transmitted disease) or STI (sexually transmitted infection): Should we choose? Janet Byron Anderson, PhD 1. Clinical foundation of the problem Another surprise: Documented incidence had shown Each of the terms—“sexual(ly)”, “transmitted”, “disease”, that the two routes of sexual transmission were male-to- and “infection”—is problematic independently, as this female and male-to-male. However, on 15 July 2016 the study will show. Moreover, co-occurring variants, used CDC reported the first case of suspected female-to-male as synonyms in English medical articles worldwide, ag- sexual transmission in New York City [4]. Since 2008, gravate the problem. The purpose of this study is to pro- then, the Zika virus has shown that it is now sexually pose a single term that can stimulate discussion about transmissible. “Transmissible” denotes a potential, and is whether the co-occurring variants are clinically and lin- distinct from “transmitted”, which denotes a reality. guistically justifiable—especially now, when STDs/STIs To say that Zika has proved to be transmissible through have become a global health problem, and public health sexual contact means that it can be transmitted through agencies in every country are scrambling to educate their sex but that it need not be (Zika remains a chiefly vec- citizens. [Until the presentation advances to the point tor-borne disease). However, cases reported since 2008 where the question posed in the title can be definitively document the reality of transmittedness through sexual answered, I’ll use the expression “STD/STI” or the terms contact. “illness(es)” and “condition(s)”.] The predisposing epidemiologic context will first be clar- This carefully differentiated language is used by the ified, for it sheds light on two of the problematic terms: European Centre for Disease Prevention and Control chiefly “transmitted” but also “sexual(ly)”.
    [Show full text]
  • Sexually Transmitted Infections Treatment Guidelines, 2021
    Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 70 / No. 4 July 23, 2021 Sexually Transmitted Infections Treatment Guidelines, 2021 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS Introduction ............................................................................................................1 Methods ....................................................................................................................1 Clinical Prevention Guidance ............................................................................2 STI Detection Among Special Populations ............................................... 11 HIV Infection ......................................................................................................... 24 Diseases Characterized by Genital, Anal, or Perianal Ulcers ............... 27 Syphilis ................................................................................................................... 39 Management of Persons Who Have a History of Penicillin Allergy .. 56 Diseases Characterized by Urethritis and Cervicitis ............................... 60 Chlamydial Infections ....................................................................................... 65 Gonococcal Infections ...................................................................................... 71 Mycoplasma genitalium .................................................................................... 80 Diseases Characterized
    [Show full text]
  • Transmission of SARS-Cov-2: Implications for Infection Prevention Precautions
    Transmission of SARS-CoV-2: implications for infection prevention precautions Scientific brief 9 July 2020 This document is an update to the scientific brief published on 29 March 2020 entitled “Modes of transmission of virus causing COVID-19: implications for infection prevention and control (IPC) precaution recommendations” and includes new scientific evidence available on transmission of SARS-CoV-2, the virus that causes COVID-19. Overview This scientific brief provides an overview of the modes of transmission of SARS-CoV-2, what is known about when infected people transmit the virus, and the implications for infection prevention and control precautions within and outside health facilities. This scientific brief is not a systematic review. Rather, it reflects the consolidation of rapid reviews of publications in peer-reviewed journals and of non-peer-reviewed manuscripts on pre-print servers, undertaken by WHO and partners. Preprint findings should be interpreted with caution in the absence of peer review. This brief is also informed by several discussions via teleconferences with the WHO Health Emergencies Programme ad hoc Experts Advisory Panel for IPC Preparedness, Readiness and Response to COVID-19, the WHO ad hoc COVID-19 IPC Guidance Development Group (COVID-19 IPC GDG), and by review of external experts with relevant technical backgrounds. The overarching aim of the global Strategic Preparedness and Response Plan for COVID-19(1) is to control COVID-19 by suppressing transmission of the virus and preventing associated illness and death. Current evidence suggests that SARS-CoV-2, the virus that causes COVID-19, is predominantly spread from person-to-person.
    [Show full text]
  • Supporting North Carolina's Vaccination Efforts
    Supporting North Carolina’s Vaccination Efforts Toolkit for Partner Organizations Updated June 17th, 2021 Current State of North Carolina COVID-19 Vaccinations: COVID-19 vaccines are available for free in North Carolina to everyone ages 12 and older. Those 18 and over can receive any of the three approved vaccines, while youth aged 12-17 may only receive the Pfizer vaccine. Individuals and CBOs may use the CDC Vaccine Finder to find locations that carry the Pfizer vaccine. While walk-in vaccinations are available, some locations may require appointments. In North Carolina, anyone can get vaccinated regardless of immigration status – getting vaccinated will not affect your immigration. No government-issued ID or insurance is required. Everyone can read the frequently asked questions on the DHHS website to learn more about vaccinations and what you can do after you’re vaccinated. Earning the Trust of North Carolinians: The injustices that drive the disparate impact of COVID-19 on historically marginalized populations (HMP)1 can also cause very legitimate reasons for community members to have questions about vaccines. That is why NCDHHS are working to partner with trusted leaders and organizations to provide accurate information to communities. NCDHHS is committed to earning the trust of North Carolinians related to the COVID-19 vaccine and beyond and building upon already established relationships. Organizations can consider the following strategies to support North Carolina’s vaccination efforts: 1. Share information about the COVID-19 vaccine: • Use the NCDHHS COVID-19 vaccine communications toolkit to make sure all North Carolinians have accurate and up-to-date information on the vaccine.
    [Show full text]
  • Iatrogenic Vs Natural Transmission Equinediseasecc.Org Edcc@Aaep
    Equine Disease Communication Center: Iatrogenic vs Natural Transmission Iatrogenic vs Natural Transmission What is Iatrogenic Transmission? Iatrogenic transmission of infectious disease refers to the spread of a pathogen, (bacteria or virus) through a medical procedure or treatment such as a blood transfusion, reuse of needles or IV sets, or by touching a wound on an infected horse and then handling another horse. Iatrogenic spread of Equine Infectious Anemia (EIA) and Equine Piroplasmosis is often due to the reuse of needles or syringes without sterilization. What is Natural Transmission? Natural transmission refers to the spread of a pathogen through direct contact transmission (horse-to horse contact), by indirect contact transmission (contact with a contaminated surface), by means of an insect vector such as biting flies, mosquitoes, by ticks, or via aerosol spread (contaminated droplets spread by coughing or sneezing that are then inhaled or come in direct contact with the eyes, nose, or mouth). Respiratory diseases such as Equine Herpesvirus and Equine Influenza are often spread by direct contact transmission, contact with contaminated surfaces, contaminated water sources and/or aerosol spread. Arboviruses, such as West Nile Virus, Eastern Equine Encephalitis, and Western Equine Encephalitis are viruses that are transmitted by biting insects and cannot be spread by direct contact or from an infected horse to humans or visa versa. How can I Prevent Iatrogenic Transmission? Always use new or sterilized equipment for medical procedures: • Needles and syringes for both IV (intravenous) and IM (intramuscular) injections are single use only. o Use a new hypodermic needle for every injection on every horse.
    [Show full text]